Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder

AIMS: When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended‐release (viloxazine ER) using measures of effect s...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Azmi, Kosheleff, Alisa R., Hull, Joseph T., Liranso, Tesfaye, Qin, Peibing, Busse, Gregory D., Fava, Maurizio, Maletic, Vladimir, Rubin, Jonathan, Lopez, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365735/
https://www.ncbi.nlm.nih.gov/pubmed/33971070
http://dx.doi.org/10.1111/ijcp.14330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365735/
https://www.ncbi.nlm.nih.gov/pubmed/33971070
http://dx.doi.org/10.1111/ijcp.14330

Ejemplares similares